• Clinical Trials - Rectal cancer

    Study Objective Contact
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision [LCID Study Number: 2012-066] This protocol compares the effects of standard treatment (chemotherapy and radiation) to chemotherapy and selective use of standard treatment before surgery for rectal cancer. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras,
    Erin H. Hartnett.
    Open-Label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator's Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorectal Cancer and Acquired Resistance to anti-EGFR Monoclonal Antibodies [LCID Study Number: 2014-022] The purpose of this study is to investigate whether patients with metastatic colorectal cancer who have previously received treatment with drugs such as Erbitux and Vectibix benefit from treatment with two different doses of an investigational drug and to compare its effects with either one of two existing cancer treatments or best supportive care (treatment for the symptoms of disease but without any anti-cancer treatment). Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Kori D. Hesse.